Morgan Stanley Other Receivables increased by 3.0% to $4.59B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.3%, from $4.16B to $4.59B. Over 3 years (FY 2021 to FY 2024), Other Receivables shows an upward trend with a 4.3% CAGR.
Significant fluctuations may indicate one-time events or changes in non-operating business activities.
This category includes miscellaneous claims for cash that are not derived from standard trade sales of pharmaceutical pr...
Varies widely based on the complexity of a company's tax structure and collaborative R&D agreements.
other_receivables| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.73B | $3.72B | $3.78B | $3.92B | $4.12B | $4.03B | $4.20B | $4.23B | $4.23B | $4.23B | $4.17B | $4.16B | $4.23B | $4.26B | $4.45B | $4.59B |
| QoQ Change | — | -0.2% | +1.6% | +3.8% | +5.0% | -2.1% | +4.1% | +0.7% | -0.0% | +0.1% | -1.6% | -0.1% | +1.6% | +0.8% | +4.5% | +3.0% |
| YoY Change | — | — | — | — | +10.6% | +8.4% | +11.1% | +7.8% | +2.6% | +5.0% | -0.8% | -1.7% | -0.0% | +0.7% | +6.9% | +10.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.